Perigon Wealth Management LLC Invests $574,000 in Edwards Lifesciences Corporation $EW

Perigon Wealth Management LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,349 shares of the medical research company’s stock, valued at approximately $574,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Commerzbank Aktiengesellschaft FI acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $305,000. Rice Hall James & Associates LLC purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $444,000. Trust Co. of Vermont acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $281,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $126,121,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $438,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. BTIG Research upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Stock Up 1.5%

EW stock opened at $92.36 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company’s 50 day simple moving average is $89.03 and its 200-day simple moving average is $84.57. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The firm has a market capitalization of $53.18 billion, a PE ratio of 53.08, a P/E/G ratio of 2.29 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the firm posted $0.67 EPS. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,570 shares of company stock valued at $2,219,390 in the last ninety days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.